SEC Company Response from ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514) (ADMA) — Mar 23, 2012
ADMA BIOLOGICS, INC. (ADMA) (CIK 0001368514)
Date: March 23, 2012 · CIK: 0001368514 · Accession: 0001193805-12-000535
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-52120
Referenced dates: March 9, 2012
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance ADMA Biologics, Inc. Form 8-K Filed February 13, 2012 File No. 000-52120
Dear Mr. Dobbie:
By letter dated March 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”). The Company currently expects that the audit of the consolidated financial statements as of and for the periods ended December 31, 2011 and 2010 will be completed during the week of March 26, 2012. It therefore expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing containing such financial statements, on or before March 30, 2012.
If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at our outside counsel, SNR Denton US LLP, at (973) 912-7100.
Sincerely,
/s/ Adam S. Grossman
Show Raw Text
CORRESP
1
filename1.htm
Unassociated Document
[ADMA LETTERHEAD]
March 23, 2012
VIA EDGAR
Mr. Justin Dobbie
Legal Branch Chief
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
ADMA Biologics, Inc.
Form 8-K
Filed February 13, 2012
File No. 000-52120
Dear Mr. Dobbie:
By letter dated March 9, 2012, you provided comments on the above-referenced filing of ADMA Biologics, Inc. (the “Company”). The Company currently expects that the audit of the consolidated financial statements as of and for the periods ended December 31, 2011 and 2010 will be completed during the week of March 26, 2012. It therefore expects to submit its response letter via EDGAR, along with an amendment to the above-referenced filing containing such financial statements, on or before March 30, 2012.
If you have any questions, or if we may be of any assistance, please do not hesitate to contact the undersigned at (201) 478-5552 or Jeffrey Baumel or Roland Chase at our outside counsel, SNR Denton US LLP, at (973) 912-7100.
Sincerely,
/s/ Adam S. Grossman
Adam S. Grossman
President and Chief Executive Officer